MedTrace Logo

Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies

NCT03156595 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2021-10-19

No results posted yet for this study

Summary

Chimiotherapy produces neuropathies injuries to 30% to 70% cases. A third of those patients keeps suffering from this side effects disabilities and their quality of life is seriously affected.

Hypnosis, as a non-invasive tool without physical side effects, might be used to relieve them.

the purpose of this trial based on our own experience, is to demonstrate the value of using hypnosis and self-hypnosis in chimiotherapy- induced chronic neuropathies.

The aim will be to sustainably improve the quality of life by expanding self-management of pain and motor function side effect.

Conditions

  • Chemotherapy-induced Neuropathy

Interventions

BEHAVIORAL

Nurse interview

Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.

BEHAVIORAL

Hypnosis sessions

Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Caroline MAURER, Nurse · Strasbourg's University Hospitals

  • Raoul HERBRECHT, MD · Strasbourg's University Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-04
Primary Completion
2021-11-04
Completion
2021-11-04

Countries

  • France

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03156595 on ClinicalTrials.gov